HRS aims to capture real-world data on pulsed field ablation (PFA) procedures used to treat AFib. The first-of-its-kind registry will offer a long-term data collection platform, J&J MedTech said in a news release. It aims to evaluate clinical outcomes, support evidence-based practice and inform the evolution of treatment strategies in electrophysiology.
J&J MedTech said it aims to advance the science of PFA and drive progress in arrhythmia care. Sponsorship of the HRS registry builds on the company’s leadership in electrophysiology, it said.
The company is one of a handful of leaders in PFA with its Varipulse platform, competing with Medtronic and Boston Scientific. It continues to look to find ways to boost PFA’s use globally. That includes a recent reimbursement boost, as the Centers for Medicare and Medicaid Services (CMS) added AFib-treating cardiac catheter ablation procedures to its ASC-covered procedures list. This follows advocacy efforts from a range of stakeholders to enable ablation services in the fast-rising ASC setting. The decision goes into effect on Jan. 1, 2026.
Johnson & Johnson MedTech Company Group Chair of Electrophysiology and Neurovascular, Michael Bodner, spoke to MassDevice about the PFA boost recently.
“We’re sponsoring this registry to enable real-world data generation at scale across the industry to shape the future of AFib ablation. By complementing our own evidence-generation registries and studies with this data platform, we aim to shape best practices, guide continued innovation and ultimately improve outcomes for more people living with AFib,” said Bodner. “This effort reflects our long-standing commitment to partnering with the clinical community and strengthening scientific understanding, a dedication grounded in our decades of scientific expertise and leadership in electrophysiology.”
